Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	ProMIS Neurosciences	Vallon Pharmaceuticals	Emerald Health Therapeutics	Rua Life Sciences	IntelGenx Technologies
Symbol	TSE:PMN	NASDAQ:VLON	CVE:EMH	LON:RUA	CVE:IGX
Price Information
Current Price	C$0.22	$4.66	C$0.29	GBX 148.50	C$0.57
52 Week Range	N/A	N/A	N/A	N/A	N/A
MarketRank™
Overall Score	0.5	0.3	0.5	0.0	0.9
Analysis Score	0.0	0.0	0.0	0.0	0.0
Community Score	2.7	0.0	2.0	0.0	2.6
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	1.7	0.0	0.0	1.7
Earnings & Valuation Score	0.0	0.0	0.6	0.0	0.0
Analyst Ratings
Consensus Recommendation	N/A	N/A	N/A	N/A	N/A
Consensus Price Target	N/A	N/A	N/A	N/A	N/A
% Upside from Price Target	N/A	N/A	N/A	N/A	N/A
Trade Information
Market Cap	C$67.31 million	$31.74 million	C$34.02 million	£34.39 million	C$30.87 million
Beta	N/A	N/A	N/A	N/A	N/A
Average Volume	439,213	67,865	719,591	55,392	53,378
Sales & Book Value
Annual Revenue	C$1,787.00	N/A	C$13.02 million	£835,000.00	C$1.54 million
Price / Sales	37,665.92	N/A	4.57	39.45	41.31
Cashflow	C$0.00 per share	N/A	C$0.34 per share	GBX 5.94 per share	C$0.02 per share
Price / Cash	55.00	N/A	0.86	25.00	27.50
Book Value	C$0.00 per share	N/A	C$0.40 per share	GBX 17 per share	C($0.01) per share
Price / Book	-55.00	N/A	0.73	0.09	-63.33
Profitability
Net Income	N/A	N/A	N/A	N/A	N/A
EPS	C($0.02)	N/A	C($0.70)	GBX (8.20)	C($0.07)
Trailing P/E Ratio	N/A	0.00	N/A	N/A	N/A
Forward P/E Ratio	∞	∞	∞	∞	∞
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	N/A	N/A
Return on Equity (ROE)	N/A	N/A	N/A	N/A	N/A
Return on Assets (ROA)	N/A	N/A	N/A	N/A	N/A
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	35.45%	11.22%	565.41%
Current Ratio	0.52%	N/A	2.97%	1.67%	0.99%
Quick Ratio	0.46%	N/A	2.61%	1.53%	0.80%
Ownership Information
Institutional Ownership Percentage	N/A	N/A	N/A	N/A	N/A
Insider Ownership Percentage	N/A	N/A	N/A	N/A	N/A
Miscellaneous
Employees	N/A	2	161	7	48
Shares Outstanding	305.95 million	6.81 million	205.03 million	22.19 million	111.91 million
Next Earnings Date	5/12/2021 (Estimated)	7/5/2021 (Estimated)	6/17/2021 (Estimated)	N/A	5/13/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	IntelGenx Announces Intention to Amend Convertible Unsecured Promissory Notes finance.yahoo.com - April 9 at 9:06 AM
	IntelGenx is a double from here, says Leede Jones Gable cantechletter.com - March 29 at 7:18 PM
	IntelGenx Reports Fourth Quarter and Full-Year 2020 Financial Results finance.yahoo.com - March 25 at 6:11 PM
	IntelGenx Technologies (IGX) Scheduled to Post Quarterly Earnings on Thursday americanbankingnews.com - March 19 at 10:37 AM
	IntelGenx Receives USPTO Notice of Allowance for its Novel DisinteQ(TM)-Based Disintegrating THC Oral Film stockhouse.com - February 17 at 11:33 PM
	IntelGenx Receives USPTO Notice of Allowance for its Novel DisinteQ™-Based Disintegrating THC Oral Film markets.businessinsider.com - February 17 at 8:31 AM
	IntelGenx Appoints Tommy Kenny as Vice President, Intellectual Property and Legal Affairs, General Counsel morningstar.com - January 12 at 9:47 PM
	IntelGenx Technologies Corp. (IGXT) CEO Horst Zerbe on Q3 2020 Results - Earnings Call Transcript seekingalpha.com - November 12 at 11:35 PM
	IntelGenx Announces Issuance of U.S. Patent for Novel Technology Applicable to ... apnews.com - November 12 at 6:34 PM
	IntelGenx Reports Third Quarter 2020 Financial Results markets.businessinsider.com - November 12 at 6:34 PM
	IntelGenx: 3Q Earnings Snapshot houstonchronicle.com - November 12 at 6:34 PM
	IntelGenx Announces Issuance of U.S. Patent for Novel Technology Applicable to Cannabis-Containing Oral Films markets.businessinsider.com - November 11 at 12:31 PM
	IntelGenx Announces Publication of a Study Evaluating Montelukast's Effect on Neurological Aging marketwatch.com - November 9 at 8:20 PM
	IntelGenx Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological Aging news.yahoo.com - November 9 at 9:52 AM
	Heritage Cannabis Signs Letter of Intent with IntelGenx for Long-Term Cannabis Filmstrip Supply Agreement news.yahoo.com - October 29 at 10:05 AM
	IntelGenx Signs Letter of Intent with Heritage Cannabis for Long-Term Cannabis Filmstrip Supply Agreement news.yahoo.com - October 29 at 10:05 AM
	Tetra Bio-Pharma gets global rights to Adversa mucoadhesive technology for its Dronabinol drug from IntelGenx proactiveinvestors.com - October 28 at 12:29 PM
	IntelGenx Amends Stock Options benzinga.com - August 24 at 6:21 PM
	IntelGenx Enters into Feasibility Agreement with ATAI Life Sciences to Develop Pharmaceutical-Grade Polymeric Film-Based Psychedelics benzinga.com - August 20 at 9:03 AM
	IntelGenx Reports Amendment of Stock Option Plan finance.yahoo.com - July 15 at 6:21 PM
	IntelGenx Announces Intention to Issue Shares in Payment of Principal on Outstanding Debentures, and Meeting of Debentureholders www.wallstreet-online.de - May 28 at 8:15 AM
	IntelGenx Confirms Type A Meeting with the FDA Regarding RIZAPORT® VersaFilm® www.benzinga.com - May 27 at 9:27 AM
	IntelGenx Announces Intention to Amend Convertible Debentures www.benzinga.com - May 12 at 9:06 AM
	IntelGenx Provides Commercial Update on its Two Lead VersaFilm® Product Candidates, Cannabis-Infused Oral Film and RIZAPORT® markets.businessinsider.com - January 13 at 5:09 PM
	IntelGenx Enters Animal Health Market by Signing Feasibility Agreement for VetaFilm™ Platform www.globenewswire.com - January 9 at 4:22 PM

Date	Company	Brokerage	Action
2/17/2019	ProMIS Neurosciences	Noble Financial	Reiterated Rating
10/11/2019	Emerald Health Therapeutics	Jefferies Financial Group	Lower Price Target
8/11/2020	Rua Life Sciences	Shore Capital	Reiterated Rating
10/28/2019	IntelGenx Technologies	Echelon Wealth Partners	Reiterated Rating
5/15/2018	IntelGenx Technologies	HC Wainwright	Lower Price Target

(Data available from 4/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources